- Home
- RMCF vs NSRX Comparison
RMCF vs NSRX Comparison
Compare RMCF & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RMCF | NSRX |
|---|---|---|
| Founded | 1981 | 2019 |
| Country | United States | Israel |
| Employees | N/A | 7 |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.2M | 32.2M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | RMCF | NSRX |
|---|---|---|
| Price | $1.97 | $3.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $19.67 |
| AVG Volume (30 Days) | ★ 49.2K | 48.3K |
| Earning Date | 06-16-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,432,352.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.17 | $1.98 |
| 52 Week High | $2.99 | $9.99 |
Technical Indicators
Market Signals| Indicator | RMCF | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 37.21 | 62.15 |
| Support Level | $1.88 | $2.04 |
| Resistance Level | $2.18 | $3.48 |
| Average True Range (ATR) | 0.13 | 0.25 |
| MACD | -0.04 | 0.05 |
| Stochastic Oscillator | 13.33 | 82.21 |
Price Performance
Historical ComparisonAbout RMCF Rocky Mountain Chocolate Factory Inc.
Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, U-Swirl Operations, and Other t. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.
About NSRX Nasus Pharma Ltd. Ordinary Shares
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.